Cancer Family
Adnexal Neoplasm
CI-CAN-00000005Explore in graph →
Non-malignant776 active trials5 approved drugs94 evidence items
- NCIt
- C212119
Loading cancer entity…
Cancer Family
CI-CAN-00000005Explore in graph →
Clinical trials
3,521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06602063 | Surgery for Relapsed Ovarian Cancer in Precision | not yet recruiting | Phase 1 / Phase 2 | 33 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06139783 | Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors | not yet recruiting | N/A | 32 | Oncare MadridOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06977594 | Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer | not yet recruiting | N/A | 1,000 | Seoul National University HospitalOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07031908 | Minimally Invasive Interval Debulking Surgery in Advanced Ovarian Cancer(MISSION-2) | not yet recruiting | — | 40 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07028229 | Ultrasound Training Program for Gynecologic Cancer Staging in Residents(Ultra-teaching) | not yet recruiting | N/A | 6 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT06990503 | SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer | not yet recruiting | Phase 3 | 300 | Tongji HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06990516 | SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer | not yet recruiting | Phase 1 / Phase 2 | 90 | Tongji HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06973421 | Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 35 | Fudan UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06925126 | Exosome-based Recurrence Score for Post-Treatment Ovarian Cancer | not yet recruiting | — | 200 | Fudan UniversityOTHER | 0 | Apr 13, 2025 | clinicaltrials |
| NCT06887933 | A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer | not yet recruiting | Phase 4 | 67 | GlaxoSmithKlineINDUSTRY | 0 | Mar 21, 2025 | clinicaltrials |
| NCT06887673 | Lipid Mediators & Cancer: Montelukast, SPM, and Almonds | not yet recruiting | Early Phase 1 | 56 | University of South FloridaOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06871787 | Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery(INOCA) | not yet recruiting | Phase 4 | 50 | Istanbul UniversityOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06846424 | SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer | not yet recruiting | Phase 1 | 24 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06838429 | PARPi and Ovarian Cancer Survival | not yet recruiting | — | 6,000 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 0 | Feb 20, 2025 | clinicaltrials |
| NCT06825455 | Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors | not yet recruiting | Early Phase 1 | 18 | Peking UniversityOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06813001 | ACT-Based Nursing Intervention for Ovarian Cancer Patients: A Pilot Study | not yet recruiting | N/A | 25 | Yonsei UniversityOTHER | 0 | Feb 6, 2025 | clinicaltrials |
| NCT06787807 | Proteomic Analysis of Patients Undergoing Bariatric Surgery | not yet recruiting | N/A | 103 | Universidade Federal de PernambucoOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06777147 | Reproductive Health Outcomes in Young Patients With Ovarian Cancer After Surgical Treatment: A Retrospective Study | not yet recruiting | — | 50 | Assiut UniversityOTHER | 0 | Jan 15, 2025 | clinicaltrials |
| NCT06751485 | JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer | not yet recruiting | Phase 3 | 430 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 0 | Dec 31, 2024 | clinicaltrials |
| NCT06748872 | EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma(EPITOME-1015-I) | not yet recruiting | Phase 1 | 55 | Medigene AGINDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06730581 | Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors | not yet recruiting | Phase 2 | 100 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Dec 12, 2024 | clinicaltrials |
| NCT06703112 | Establishment and Clinical Application of AI-based Multimodal Diagnosis System for Ovarian Tumors | not yet recruiting | N/A | 584 | Beijing Shijitan Hospital, Capital Medical UniversityOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06673511 | The Application of Sentinel Lymph Node Mapping Technique in the Surgery of Early Epithelial Ovarian Cancer | not yet recruiting | N/A | 246 | Anhui Provincial HospitalOTHER_GOV | 0 | Nov 21, 2024 | clinicaltrials |
| NCT06553742 | High Definition Profiling of Ovarian Cancer Ascites | not yet recruiting | — | 50 | European Institute of OncologyOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06652529 | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors(AROG4-01-01) | not yet recruiting | Phase 1 | 35 | Aromics TherapeuticsINDUSTRY | 0 | Nov 7, 2024 | clinicaltrials |
| NCT06650709 | NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study(NEOCATS) | not yet recruiting | Phase 2 | 40 | British Columbia Cancer AgencyOTHER | 0 | Oct 23, 2024 | clinicaltrials |
| NCT06620029 | BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer | not yet recruiting | Phase 1 / Phase 2 | 27 | BioMimetix JV, LLCINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06617585 | The Role of CircDENND4C in Epithelial Ovarian Cancer | not yet recruiting | — | 30 | Assiut UniversityOTHER | 0 | Sep 27, 2024 | clinicaltrials |
| NCT06600841 | Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer | not yet recruiting | Phase 2 | 37 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06558019 | Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence | not yet recruiting | — | 509 | Lei LiOTHER | 1 | Aug 16, 2024 | clinicaltrials |
| NCT06552858 | Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06544460 | Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients | not yet recruiting | Phase 2 | 94 | Fudan UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06541171 | A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results(FOFU) | not yet recruiting | — | 220 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06542549 | Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer | not yet recruiting | Phase 3 | 100 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 7, 2024 | clinicaltrials |
| NCT06539091 | Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer | not yet recruiting | Phase 3 | 51 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 6, 2024 | clinicaltrials |
| NCT06531486 | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 96 | NovaOnco Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 1, 2024 | clinicaltrials |
| NCT06528236 | Research and Application of Ultrasonic Intelligent Diagnosis System for Ovarian Mass | not yet recruiting | — | 100,000 | Zhejiang Provincial People's HospitalOTHER | 0 | Jul 30, 2024 | clinicaltrials |
| NCT05924776 | Plasmodium Immunotherapy for Advanced Ovarian Cancer | not yet recruiting | Phase 2 / Phase 3 | 30 | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.INDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06283875 | The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer | not yet recruiting | — | 80 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05921149 | Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer | not yet recruiting | N/A | 170 | Endeavor HealthOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06393543 | International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis(STICRISC) | not yet recruiting | — | 600 | Radboud University Medical CenterOTHER | 0 | May 1, 2024 | clinicaltrials |
| NCT06383507 | A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors | not yet recruiting | Phase 1 | 18 | Zhejiang UniversityOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT06315270 | To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer | not yet recruiting | — | 100 | The First Hospital of Jilin UniversityOTHER | 0 | Apr 1, 2024 | clinicaltrials |
| NCT06329323 | SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours(SUMMER) | not yet recruiting | — | 24 | Imperial College LondonOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06188455 | Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer | not yet recruiting | Phase 3 | 37 | The First Affiliated Hospital of Xiamen UniversityOTHER | 0 | Jan 3, 2024 | clinicaltrials |
| NCT06081595 | Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment | not yet recruiting | Phase 2 | 54 | Jin LiOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT06070285 | Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06063070 | First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer | not yet recruiting | Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT05794659 | Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer(Cornerstone4) | not yet recruiting | Phase 2 | 98 | Aston Sci. Inc.INDUSTRY | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05931055 | The Effectiveness of Liquid Biopsy in Differential Diagnosis and Early Screening of Epithelial Ovarian Cancer | not yet recruiting | — | 1,000 | Peking Union Medical College HospitalOTHER | 0 | Jul 5, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 27, 2025source: clinicaltrials